CERTIFICATION OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facaimile transmitted to the Patent and Trademark Office on the date shown below. Type or print name of person signing certification Signature Date

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: BELL Michael Gregory	
Serial No.:	:
Application Date:	
US Nat'l Entry Date (if applicable):	
For: COMPOUNDS AND METHODS FOR TREATING DYSI	IPIDEMIA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: X-16723

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the foreign patent and /or published application and each non-patent reference for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted.

/James B. Myers/ James B. Myers Attorney for Applicants Registration No. 42,021 Phone: 317-276-0755

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

August 31, 2006

FORM PTO 1449 (modified)	Atty, Docket No.	Serial No
	X-16723	
INFORMATION DISCLOSURE CITATION	First Applicant	
IN AN APPLICATION	BELL, Michael Gregory	
	US Nat'l Entry (if applicable)	Group Art Unit
		-

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear	
	AA	US 6,147,090	11-14-2000	DeNinno, et. al.		
	AB	US 2005/0059810	03-17-2005	Maeda, et. al.		
	AC	US 5932587	08-03-1999	Schmeck, et. al.		

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴⁻ Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6
	BA	EP 0992496	12-04-2000	Pfizer Products, Inc.		
	BB	JP 2003321472A	11-11-2003	Takeda Chemical Industries LTD.		
	BC	UK 1 515 540	6-28-1978	Maurice Prost		
	BD	WO 05/095395	10-13-2005	Tanable		
	BE	WO 00/17166 A	03-30-2000	Pfizer Products, Inc.		
				TURE DOCUME		
Examiner Initials*	Cite No. 1	(book, magazine, journal, s	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.			T ⁶
	CA	Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DF; BRN 584498, 1993, XP 002333708, Abstract, Maurice, et al., "Decahydroquinoline derivatives. VIII. 4-Amilino- and 4-amildodecahydroquinolines and N-substituted derivatives" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 15(3), 215-22 ODEN: EJMCA5; ISSN: 6009-4374, 1980.				
CB Bisgaier et al. <u>J of Lipid Res.</u> 1993, 34 , 1625-1634						

Examiner	/Niloofar Rahmani/	Date Considered	10/21/2008
Signature			

^{*}EXAMPLER: Inttal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique critistion designation number (optional). ² See Kinds Codes of USFTO Photo December at a <u>new number to very the PSF 901.04</u>. ³ Date Office that moved the document, by the residence of the WDF of Seathed 255. ³ To be placed possible and the contract of the position of the posi